Dr. Patrick Soon-Shiong Selected to Join the National Cancer Institute's Blue Ribbon Panel

Physician Scientist and inventor of Abraxane to participate with 28 cancer community thought leaders to help inform the scientific direction at the NCI of the [National Cancer Initiative]

CULVER CITY, Calif. – April 7, 2016 ‎– The National Cancer Institute announced the selection of Patrick Soon-Shiong, M.D., FRCs (c), FACS to the Blue Ribbon Panel of scientific experts, cancer leaders and patient advocates that will inform the scientific direction and goals at the [institute] of Vice President Joe Biden’s [National Cancer Initiative].

Dr. Soon-Shiong will be a member of the panel of experts that will provide recommendations to the National Cancer Advisory Board, which advises the NCI, on how to advance the themes that have been proposed for the initiative. The themes include the development of cancer vaccines, highly sensitive approaches to early detection, advances in immunotherapy and combination therapies, single-cell genomic profiling of cancer cells and cells in the tumor microenvironment, enhanced data sharing, and new approaches to the treatment of pediatric cancers.

The 28-member Blue Ribbon Panel brings together a group of cancer thought leaders to address opportunities in prevention, diagnosis and treatment of cancer. The panel includes extramural investigators, members of the public, cancer advocacy groups, pharmaceutical and biotechnology industries and communities with expertise in clinical trials and health disparities. 

“It’s an extremely exciting time in the history of the war against cancer— our program, [Cancer Breakthroughs 2020], and Vice President Biden’s [initiative] are important calls to action to urge collaboration in order to make impactful strides, accelerate progress, and win this war,” said Patrick Soon-Shiong, CEO of NantWorks and leader of the [Cancer Breakthroughs 2020], a non-profit cancer collaborative. “It’s an honor to join the Blue Ribbon Panel and have the opportunity to share the steps we have already taken with [Cancer Breakthroughs 2020] to accelerate immunotherapy development and drive comprehensive pan-omic precision cancer care. We are most excited by the strides we have made in engaging both community oncologists and the pediatric community in our efforts to establish a [network] to accelerate clinical trials,” he said.

Dr. Soon-Shiong, founder of the [Cancer Breakthroughs 2020] program, a cancer collaborative formed to accelerate next-generation immunotherapy in cancer, has dedicated his medical and scientific efforts to addressing the biological complexities of cancer. He developed the nation's first biologically active chemotherapy, an albumin bound nanoparticle of paclitaxel, designed to enter the tumor microenvironment, which is approved today for the treatment of breast, lung and pancreatic cancer. For over a decade, Dr. Soon-Shiong has championed the paradigm-shifting administration of low dose combination chemotherapy to protect the patient's immune system.   In January 2016 at the J.P. Morgan 34th Annual Healthcare Conference, Dr. Soon-Shiong along with industry leaders from Celgene and Amgen and multiple biotech companies, major payers, Independence Blue Cross and Fortune 50 companies, academia and community oncologists announced the launch of the [Cancer Breakthroughs 2020] program www.cancerbreakthroughs2020.org. The program focuses on treating cancer following comprehensive genomic and proteomic analysis of the tumor, with combination chemo, targeted and immunotherapies, forming a key point for discussions on the Blue Ribbon Panel. 

The goal of the [Cancer Breakthroughs 2020] program is to evaluate novel combination immunotherapies as the next generation standard of care. Members of the program have been brought together to complete randomized clinical trials in patients with cancer at all stages of disease. This will be conducted through the Quantitative Integrative Lifelong Trial (QUILT) program, which aims to test multiple combinations of therapies on up to 20,000 patients who have undergone next-generation whole genome, transcriptome and quantitative proteomic analysis.

About [Cancer Breakthroughs 2020]

The [Cancer Breakthroughs 2020] Program is one of the most comprehensive cancer collaborative initiative launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational Breakthroughs to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, visit www.cancerbreakthroughs2020.org.